1. Memori
  2. ›
  3. Articles

Should the Mumps Vaccine Stay "Optional"? — Hearing Loss Risk and Vaccination Coverage

By Leon MoriguchiPublished May 15, 2026Updated May 18, 20265 min read日本語版あり
Audience
Parents uncertain about whether to give their child the mumps vaccine

TL;DR

  • ·Mumps-related sensorineural hearing loss is rare in absolute terms but essentially permanent when it occurs — there is no effective treatment after onset, which sets it apart from most other mumps sequelae
  • ·Single-dose vaccine protection fails in roughly 20–30% of exposures; two doses aligned with the MR schedule are needed for both individual protection and preventing outbreak transmission chains
  • ·In Japan, the mumps vaccine remains optional, placing the decision entirely on parents — the current vaccines use different strains from the problematic 1990s formulation, and the Japan Pediatric Society formally recommends routine vaccination

Contents

  1. Lead
  2. The Real Complications of Mumps
  3. Why Is the Vaccine Still "Optional" in Japan?
  4. Why One Dose Is Not Enough
  5. Making the Decision
  6. Summary
  7. References

Lead

Mumps carries a reputation for being mild. But one of its complications — hearing loss — can be permanent, unilateral, and irreversible. There is no treatment; once it occurs, it cannot be undone. That quality sets mumps-related hearing loss apart within the spectrum of mumps sequelae.

In Japan, the mumps vaccine is not part of the routine immunization schedule. That means the decision whether to vaccinate falls entirely to the parent. This article reviews the real rates of mumps complications and what is currently known about the vaccine.

The Real Complications of Mumps

Mumps virus infection extends well beyond the classic parotid gland swelling. A comprehensive review by Hviid et al. reports aseptic meningitis: inflammation of the membranes around the brain caused by a virus rather than bacteria, usually self-resolving in 1–10% of cases, orchitis: painful inflammation of one or both testes, a serious mumps complication in post-pubertal males (in post-pubertal males) in 20–38%, and sensorineural hearing loss: permanent hearing impairment from damage to the inner ear or auditory nerve, not the middle ear in 1 in 15,000 to 1 in 20,000 cases [1].

The hearing loss rate may look small in absolute terms, but the key issue is its nature: unilateral and essentially permanent. Direct viral invasion of the inner ear combined with vascular damage is thought to be the mechanism, and there is almost no effective treatment after onset [1,3]. Mumps virus is a non-trivial cause of acquired unilateral hearing loss in childhood.

Aseptic meningitis generally resolves without serious sequelae, but when encephalitis develops as a complication, outcomes can be severe.

Why Is the Vaccine Still "Optional" in Japan?

While most countries include a mumps vaccine as part of the MMR (measles-mumps-rubella) combination given in routine childhood schedules, Japan has kept mumps vaccination optional since the early 1990s.

The historical context: from 1989 to 1993, the MMR vaccine in Japan (containing the Urabe strain) was associated with a high rate of vaccine-induced aseptic meningitis, leading to the discontinuation of MMR. Since then, monovalent mumps vaccine has continued on an optional basis, and the debate over reintroducing routine mumps vaccination has been shadowed by the question of balancing vaccine-strain meningitis risk against the risk of disease-related complications [1].

The monovalent vaccines currently used for optional vaccination in Japan, however, are two products based on the Hoshino and Torii strains — different strains from the Urabe strain in the discontinued MMR [8]. Vaccine-associated aseptic meningitis is not zero. But in a 2000–2003 prospective comparative study, it occurred in 1.24% (13/1,051) of children with symptomatic natural mumps versus 0.05% (10/21,465) of vaccine recipients — far less often after vaccination [6]. Rates have fallen further since. In reports received by the Torii-strain manufacturer, the incidence has stayed below 3 per 100,000 doses since 2010 [7]; a 2020–2023 nationwide prospective survey, which actively sought out cases rather than waiting for reports, found 13.4 per 100,000 doses (about 1 in 7,500) among children vaccinated between age one and school entry [5,8]. Vaccination before age three has been associated with a lower risk, and the shift toward vaccinating at age one is thought to have contributed to the decline [7,8].

In May 2026, Japan approved a domestic MMR vaccine containing the RIT-4385 strain — the mumps strain used in MMR vaccines abroad and considered to cause aseptic meningitis only very rarely (not yet in use as of that month) [8]. In June 2026, the Japan Pediatric Society asked the Minister of Health, Labour and Welfare to add mumps to the diseases covered by the Immunization Act and to bring this MMR vaccine into the routine schedule as quickly as possible, while also allowing the existing monovalent vaccine combined with the MR vaccine to be used for routine vaccination [5].

Why One Dose Is Not Enough

Breakthrough infection: infection that occurs in a vaccinated individual when the vaccine does not provide complete protection after a single mumps vaccine dose — infection despite vaccination — occurs in roughly 20–30% of exposed individuals, depending on the study [2,4]. In outbreak settings, single-dose recipients have been documented as transmission sources [2].

For this reason, two doses are recommended — timed to align with the MR (measles-rubella) schedule: once around the first birthday and once the year before primary school entry [5]. If the vaccination record in your child's Maternal and Child Health Handbook (boshi techo) shows only one dose, it is worth asking your pediatrician about the second.

Making the Decision

  • The mumps vaccine can be given at the same visits as the routine MR vaccine (first dose around age one, second dose the year before school entry). It involves an out-of-pocket fee, but weighing infection risk, cost, and logistics is a reasonable place to start.
  • If a child develops "one ear seems not as sharp after mumps," or seems to frequently ask for repetition in noisy environments, an audiological evaluation by an ENT specialist sooner rather than later is worth pursuing. Children often don't notice unilateral hearing loss themselves.
  • Vaccination doesn't reduce the risk of infection to zero, but it substantially lowers the probability of severe illness and complications.

Summary

Mumps-related hearing loss is infrequent but irreversible when it occurs. Single-dose protection is incomplete, and multiple studies support the value of two doses. In Japan, "optional" means the decision is the parent's to make — not that it does not need to be made. Knowing the actual complication rates and the current state of the evidence is the starting point for that conversation with your pediatrician.

References

  1. Hviid A, Rubin S, Mühlemann K. Mumps. Lancet. 2008;371(9616):932–944. doi:10.1016/S0140-6736(08)60419-5. PMID: 18342688.
  2. Barskey AE, Schulte C, Rosen JB, et al. Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med. 2012;367(18):1704–1713. doi:10.1056/NEJMoa1202865. PMID: 23113481.
  3. Vuori M, Lahikainen EA, Peltonen T. Perceptive deafness in connection with mumps. Acta Otolaryngol. 1962;55:231–236. PMID: 13998066.
  4. Yoshida N, Fujino M, Miyata A, et al. Mumps virus reinfection is not a rare event confirmed by reverse transcription loop-mediated isothermal amplification. J Med Virol. 2008;80(3):517–523. doi:10.1002/jmv.21106. PMID: 18205215.
  5. Japan Pediatric Society. Request for early routine vaccination with mumps-containing vaccines and use of already-approved vaccines (letter to the Minister of Health, Labour and Welfare) [in Japanese]. June 4, 2026. https://www.jpeds.or.jp/society-activities/pediatric-medical-care/vaccination/vaccinations-infectiousdiseases/post-157644.html
  6. Nagai T, Okafuji T, Miyazaki C, et al. A comparative study of the incidence of aseptic meningitis in symptomatic natural mumps patients and monovalent mumps vaccine recipients in Japan. Vaccine. 2007;25(14):2742–2747. doi:10.1016/j.vaccine.2005.11.068. PMID: 16530894.
  7. Ohfuji S, Tanaka T, Nakano T, et al. Annual trends in adverse events following mumps vaccination in Japan: A retrospective study. Vaccine. 2022;40(7):988–993. doi:10.1016/j.vaccine.2022.01.008. PMID: 35058077.
  8. Japan Institute for Health Security, National Institute of Infectious Diseases. Mumps vaccine fact sheet, 2nd ed. [in Japanese]. Revised June 19, 2026. https://www.mhlw.go.jp/content/10900000/001713315.pdf

In the memori app

The memori app mirrors what goes into your child's health handbook.

  • Vaccinations show what's done and what's next, with a nudge as the window approaches.
  • Checkups, newborn screening and the rest of the health handbook can be mirrored into the app.
  • Medical subsidy certificates can be stored as well.
Try memori
← PreviousPool Fever Isn't Only a Summer Thing — A Complete Picture of Adenovirus InfectionNext →From "Everyone Gets It" to "Most Don't Anymore" — Varicella Vaccination in Japan Since 2014

Related

  • The "Happy Spitter" and the Line It Shouldn't Cross — GER vs. GERD in Infants
  • What "A Measles Case in Japan" Actually Means — Imported Cases and Severity After WHO Elimination Certification
  • When Your Baby Hasn't Pooped in Three Days — Functional Constipation and When to Think of Hirschsprung Disease